| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Oseltamivir acid methyl ester hydrochloride is a prodrug that targets the enzyme carboxylesterase 1 (CES1), which converts it to the active metabolite oseltamivir acid. Oseltamivir acid then targets the viral neuraminidase enzyme, inhibiting the release of influenza virus from infected cells. Therefore, the primary biological target is CES1 for activation, followed by neuraminidase for antiviral activity.
|
|---|---|
| ln Vitro |
As a prodrug, the in vitro activity of Oseltamivir acid methyl ester hydrochloride is dependent on conversion to oseltamivir acid by CES1. The parent compound itself has weak antiviral activity, but after hydrolysis, the active metabolite oseltamivir acid is a potent and selective inhibitor of influenza neuraminidase, with IC50 values in the low nanomolar range (typically 0.5-10 nM depending on the viral strain).
|
| ln Vivo |
Specific in vivo activity data is not provided, but oseltamivir acid methyl ester is the immediate precursor to oseltamivir acid, the active metabolite of the approved antiviral drug oseltamivir phosphate (Tamiflu). In vivo, after oral administration of oseltamivir phosphate, it is converted to oseltamivir acid methyl ester and then to oseltamivir acid, which effectively reduces viral replication and symptom duration in influenza-infected patients.
|
| Enzyme Assay |
The conversion of Oseltamivir acid methyl ester hydrochloride to oseltamivir acid by CES1 can be measured using an in vitro hydrolysis assay. Procedure: Recombinant human CES1 enzyme (10 ug) is incubated with varying concentrations of Oseltamivir acid methyl ester hydrochloride (0.1-100 uM) in 100 mM Tris-HCl buffer (pH 7.4) at 37degC for 30 minutes. The reaction is stopped by adding acetonitrile. The amount of oseltamivir acid produced is quantified by LC-MS/MS. The kinetic parameters Km and Vmax are calculated using Michaelis-Menten analysis.
|
| Cell Assay |
To assess the conversion in cells, hepatocytes or cell lines expressing CES1 can be used. Procedure: Primary human hepatocytes or Huh-7 cells are seeded in 24-well plates (2x10⁵ cells/well). Cells are treated with Oseltamivir acid methyl ester hydrochloride at 1, 5, and 10 uM for 24 hours at 37degC. Cell culture supernatants are collected, and the concentration of oseltamivir acid is measured by LC-MS/MS. Alternatively, the antiviral activity can be assessed by infecting MDCK cells with influenza virus, then treating with the compound and measuring viral titer by plaque assay.
|
| Animal Protocol |
The in vivo efficacy of oseltamivir acid methyl ester would be similar to that of oseltamivir phosphate. Procedure: Female BALB/c mice (6-8 weeks) are infected intranasally with 5x10⁵ PFU of influenza A virus (e.g., H1N1). Two hours post-infection, mice are treated orally with Oseltamivir acid methyl ester hydrochloride at doses of 10, 30, and 100 mg/kg twice daily for 5 days. Positive control mice receive oseltamivir phosphate (20 mg/kg). Survival, body weight, and clinical signs are monitored daily for 14 days. On day 5, lung viral titers are determined by plaque assay.
|
| ADME/Pharmacokinetics |
A specific PK profile for Oseltamivir acid methyl ester hydrochloride is not provided, but it is known to be rapidly converted to oseltamivir acid in vivo. Following oral administration, oseltamivir phosphate is absorbed and hydrolyzed to oseltamivir acid methyl ester, which is then converted to the active metabolite oseltamivir acid by CES1. The half-life of oseltamivir acid is approximately 6-10 hours in humans, and it is primarily excreted renally.
|
| Toxicity/Toxicokinetics |
Specific toxicology data is not provided, but oseltamivir phosphate is an approved drug with a well-characterized safety profile. Common adverse effects include nausea, vomiting, and headache. Rare neuropsychiatric events have been reported. As a research chemical, Oseltamivir acid methyl ester hydrochloride should be handled with standard laboratory precautions.
|
| References | |
| Additional Infomation |
Oseltamivir acid methyl ester hydrochloride is a research chemical used as an impurity standard and intermediate for the antiviral drug oseltamivir (Tamiflu). It is the methyl ester form of oseltamivir acid, the active metabolite that inhibits influenza neuraminidase. The compound is converted to oseltamivir acid by carboxylesterase 1 (CES1). It is for research use only and is not intended for human therapeutic use. The product is typically stored at -20degC as a powder and is available in various package sizes.
|
| Molecular Formula |
C15H27CLN2O4
|
|---|---|
| Molecular Weight |
334.84
|
| Exact Mass |
334.166
|
| CAS # |
208720-78-9
|
| PubChem CID |
168445018
|
| Appearance |
Typically exists as solids at room temperature
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
22
|
| Complexity |
404
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
O([C@@H]1C=C(C(=O)OC)C[C@H](N)[C@H]1NC(=O)C)C(CC)CC.Cl
|
| InChi Key |
VXUUEBWFJPUQGY-SOIKFHLCSA-N
|
| InChi Code |
InChI=1S/C15H26N2O4.ClH/c1-5-11(6-2)21-13-8-10(15(19)20-4)7-12(16)14(13)17-9(3)18;/h8,11-14H,5-7,16H2,1-4H3,(H,17,18);1H/t12-,13+,14+;/m0./s1
|
| Chemical Name |
methyl (3R,4R,5S)-4-acetamido-5-amino-3-pentan-3-yloxycyclohexene-1-carboxylate;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9865 mL | 14.9325 mL | 29.8650 mL | |
| 5 mM | 0.5973 mL | 2.9865 mL | 5.9730 mL | |
| 10 mM | 0.2987 mL | 1.4933 mL | 2.9865 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
